Abstract
Purpose: Many years ago, diphtheria toxin (DT) showed antitumor activity in mice and in humans, but it was unclear whether this depended on the toxicity of the molecule only or on its strong inflammatory-immunological property as well. To deal with this open question, we planned to treat a group of cancer patients with cross-reacting material 197 (CRM197). CRM197 is a nontoxic mutant of DT that shares the immunological properties of the native molecule and its ability to bind to heparin-binding epidermal growth factor (HB-EGF), the specific cell-membrane receptor for DT that is often overexpressed in cancer. Methods: 25 outpatients with various advanced tumors who were refractory to standard therapies (23 subjects) or had refused, in whole or in part, conventional therapies (2 subjects) were treated with CRM197 injected subcutaneously in the abdominal wall, on alternate days, for 6 days. Three different dosages (1.7, 2.6, or 3.5 mg/day) were used according to the patient’s degree of immunological reactivity to DT/CRM197 (none, moderate, or high). Results: After the first administration of CRM197, a significant increase in the number of circulating neutrophils and in the serum level of TNF-α was detected. Toxicities were minimal. Only patients with delayed-type hypersensitivity to DT/CRM197 had irritating skin reactions in the injection sites and a flu-like syndrome with fever. Pharmacokinetics showed a mean peak concentration (12.7 ng/ml) 12 h after the first injection and a mean half-life of 18.1 h. There were two complete and one partial responses (metastatic breast carcinoma, neuroblastoma, and metastatic breast carcinoma) lasting 4, 45+, and 15 months, respectively. Six cases of stable disease, lasting from 1 to 15 months, were also recorded. Conclusions: CRM197 injected subcutaneously elicited an inflammatory-immunological reaction, caused tolerable toxicities, was absorbed to a good extent into the circulatory system, and exerted some degree of biological antitumor activity. A possible role of neutrophils and TNF-α in the mode of action of the molecule is hypothesized.
Similar content being viewed by others
References
Pappenheimer AM Jr (1977) Diphtheria toxin. Ann Rev Biochem 46:69
Rappuoli R (1990) New and improved vaccines against diphtheria and tetanus: In: Woodrow GC, Levine MM (eds) New generation vaccines. Marcel Dekker, New York, p 251
Raab G, Klagsbrun M (1997) Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1333:179
Buzzi S, Maistrello I (1973) Inhibition of growth of Ehrlich tumors in Swiss mice by diphtheria toxin. Cancer Res 33:2349
Buzzi S (1982) Diphtheria toxin treatment of human advanced cancer. Cancer Res 42:2054
Buzzi S, Buzzi L (1974) Cancer immunity after treatment of Ehrlich tumor with diphtheria toxin. Cancer Res 34:3481
Buzzi S (1974) Diphtheria toxin in cancer therapy. Lancet I:628
Buzzi S, Baccini C, Rubboli D, Monti G, Buzzi G, Buzzi AM (1999) Phase I-II study of CRM197 administration to 50 advanced cancer patients. AACR.NCI.EORTC Inter Conf abstract 384
Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C, Pironi F (2002) CRM197: phagocyte mediated antitumor activity followed by a connective proliferation tending to encapsule the tumor. Proc AACR (Abstract 4529)
Harnisch JP (1980) Diphtheria. In: Isselbacher KJ, Adams RD, Braunwald E, Petersdorf RG, Wilson JD (eds) Harrison’s principles of internal medicine. McGraw-Hill, New York, p 671
Davis BD, Dulbecco R, Eisen HN, Ginsberg HS, Wood WB (1968) Microbiology. Harper & Row, New York, p 676
Wirtz M, Puccinelli M, Mele C, Gentili G (1995) Immunity to diphtheria in the 4–70 year age group in Italy. Vaccine 13:771
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, Marsden HB, Misugi K (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405
Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, Larkin EW, Holbrook CT, Silverman JF, Norris HT, Hayes FA, Smith EI, Castleberry RP (1993) Correlation between morphologic and other prognostic markers of neuroblastoma. Cancer 71:3173
Aggarwal BB (2000) Tumor necrosis factor (TNF): a double-edged sword. J Clin Ligand Assay 23:181
Roberts WG, Palade GE (1997) Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57:765
Weiss SJ (1989) Tissue destruction by neutrophils. N Engl J Med 320:365
Oberley LW, Buettner GR (1979) Role of superoxide dismutase in cancer: a review. Cancer Res 39:1141
Acknowledgements
We thank Dr Bruno Rusticali for his generous technical contribution, Dr Andrea Casadio for his helpful advice, and Dr William Vint for reviewing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buzzi, S., Rubboli, D., Buzzi, G. et al. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 53, 1041–1048 (2004). https://doi.org/10.1007/s00262-004-0546-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-004-0546-4